ECSP12011659A - Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis - Google Patents

Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis

Info

Publication number
ECSP12011659A
ECSP12011659A ECSP12011659A ECSP12011659A EC SP12011659 A ECSP12011659 A EC SP12011659A EC SP12011659 A ECSP12011659 A EC SP12011659A EC SP12011659 A ECSP12011659 A EC SP12011659A
Authority
EC
Ecuador
Prior art keywords
solid oral
inhibitor
crystalline forms
oral formulations
apoptosis protein
Prior art date
Application number
Other languages
English (en)
Inventor
Lili Feng
Jeewan Thakur
Dong Yang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP12011659A publication Critical patent/ECSP12011659A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/38—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by doubly-bound oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente divulgación se refiere a la forma cristalina de la (S)-N-((S)-1-ciclohexil-2-{(S)-2-[4-(4-fluoro-benzoil)-tiazol-2-il]-pirrolidin-1-il}-2-oxo-etil)-2-metil-amino-propionamida, a las sales e hidratos de la misma. Esta divulgación también se refiere a una formulación oral sólida de la (S)-N-((S)-1-ciclohexil-2-{(S)-2-[4-(4-fluoro-benzoil)-tiazol-2-il]-pirrolidin-1-il}-2-oxo-etil)-2-metil-amino-propionamida, a las sales farmacéuticamente aceptables y solvatos (incluyendo hidratos) de la misma, así como a los métodos para el tratamiento mediante su uso
ECSP12011659 2009-07-03 2012-01-03 Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis ECSP12011659A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0903270A FR2947546B1 (fr) 2009-07-03 2009-07-03 Derives de pyrazoles, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
ECSP12011659A true ECSP12011659A (es) 2012-03-30

Family

ID=41695643

Family Applications (2)

Application Number Title Priority Date Filing Date
ECSP12011659 ECSP12011659A (es) 2009-07-03 2012-01-03 Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis
EC2012011569A ECSP12011569A (es) 2009-07-03 2012-01-03 Derivados de pirazoles, su preparación y su aplicación terapéutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
EC2012011569A ECSP12011569A (es) 2009-07-03 2012-01-03 Derivados de pirazoles, su preparación y su aplicación terapéutica

Country Status (30)

Country Link
US (1) US8367715B2 (es)
EP (1) EP2448924B1 (es)
JP (1) JP5680640B2 (es)
KR (1) KR20120037967A (es)
CN (1) CN102471280B (es)
AR (1) AR077371A1 (es)
AU (1) AU2010267824A1 (es)
BR (1) BR112012000104A2 (es)
CA (1) CA2767096A1 (es)
CL (1) CL2012000013A1 (es)
CO (1) CO6480992A2 (es)
CR (1) CR20110701A (es)
DO (1) DOP2012000001A (es)
EA (1) EA020364B1 (es)
EC (2) ECSP12011659A (es)
FR (1) FR2947546B1 (es)
IL (1) IL217300A0 (es)
MA (1) MA33500B1 (es)
MX (1) MX2012000267A (es)
MY (1) MY155829A (es)
NI (1) NI201200001A (es)
NZ (1) NZ597578A (es)
PE (1) PE20120917A1 (es)
SG (1) SG177463A1 (es)
TN (1) TN2011000658A1 (es)
TW (1) TWI471312B (es)
UA (1) UA106500C2 (es)
UY (1) UY32757A (es)
WO (1) WO2011001122A2 (es)
ZA (1) ZA201200027B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2908409B1 (fr) 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
WO2013106432A1 (en) * 2012-01-09 2013-07-18 X-Rx, Inc. Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
KR102344105B1 (ko) 2014-08-18 2021-12-29 에자이 알앤드디 매니지먼트 가부시키가이샤 모노시클릭 피리딘 유도체의 염 및 이의 결정
EP3275442B1 (en) 2015-03-25 2021-07-28 National Cancer Center Therapeutic agent for bile duct cancer
CN108367000A (zh) 2015-12-17 2018-08-03 卫材R&D管理有限公司 用于乳腺癌的治疗剂
CN107619388A (zh) 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
CN107840842A (zh) 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
US11219619B2 (en) 2018-03-28 2022-01-11 Eisai R&D Management Co., Ltd. Therapeutic agent for hepatocellular carcinoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331541B1 (en) * 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
GB0317127D0 (en) * 2003-07-22 2003-08-27 Astex Technology Ltd Pharmaceutical compounds
EP1845975A1 (en) * 2005-01-21 2007-10-24 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors and further antitumor agents
WO2007064931A2 (en) * 2005-12-02 2007-06-07 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
EP1959947A2 (en) * 2005-12-15 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions and methods
FR2908409B1 (fr) * 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
WO2008073480A1 (en) * 2006-12-11 2008-06-19 Irm Llc Compounds and compositions as kinase inhibitors

Also Published As

Publication number Publication date
UA106500C2 (uk) 2014-09-10
PE20120917A1 (es) 2012-08-17
NI201200001A (es) 2012-03-30
WO2011001122A3 (fr) 2011-02-24
ZA201200027B (en) 2013-03-27
HK1169387A1 (en) 2013-01-25
JP5680640B2 (ja) 2015-03-04
CO6480992A2 (es) 2012-07-16
FR2947546B1 (fr) 2011-07-01
US8367715B2 (en) 2013-02-05
CN102471280B (zh) 2014-08-06
MX2012000267A (es) 2012-04-30
EP2448924B1 (fr) 2013-09-04
EA201270128A1 (ru) 2012-07-30
CL2012000013A1 (es) 2012-09-14
MY155829A (en) 2015-12-15
CN102471280A (zh) 2012-05-23
EP2448924A2 (fr) 2012-05-09
KR20120037967A (ko) 2012-04-20
EA020364B1 (ru) 2014-10-30
MA33500B1 (fr) 2012-08-01
TN2011000658A1 (fr) 2013-05-24
DOP2012000001A (es) 2012-01-31
TW201107298A (en) 2011-03-01
FR2947546A1 (fr) 2011-01-07
NZ597578A (en) 2013-11-29
TWI471312B (zh) 2015-02-01
JP2012531466A (ja) 2012-12-10
BR112012000104A2 (pt) 2016-03-15
US20120270918A1 (en) 2012-10-25
AU2010267824A1 (en) 2012-02-16
SG177463A1 (en) 2012-02-28
IL217300A0 (en) 2012-02-29
CA2767096A1 (fr) 2011-01-06
WO2011001122A2 (fr) 2011-01-06
UY32757A (es) 2011-01-31
AR077371A1 (es) 2011-08-24
CR20110701A (es) 2012-03-06
ECSP12011569A (es) 2012-02-29

Similar Documents

Publication Publication Date Title
ECSP12011659A (es) Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis
ECSP12011935A (es) Triazolopiridinas
DOP2016000250A (es) Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa
AR077765A1 (es) Inhibidores de los virus flaviviridae
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
ECSP099775A (es) Terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario
UY33452A (es) Triazolopiridinas sustituidas
CU20110145A7 (es) Derivados de sulfonamida
DOP2013000244A (es) Triazolopiridinas
DOP2014000133A (es) Triazolopiridinas sustituidas
UY30500A1 (es) Compuestos de azabencimidazolilo
CL2013001591A1 (es) Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
HN2006035237A (es) Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas
NI201600149A (es) Cromeno y 1,1a,2,7b-tetrahidrociclopropa[c]cromeno piridopirazinadionas como moduladores de gamma-secretasa
ECSP10010576A (es) Formulaciones orales e inyectables de compuestos de tetraciclina
CO6612189A2 (es) Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis
ECSP10010597A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
MX2019009224A (es) Diacilhidrazina cristalina y sus usos.
CY1118132T1 (el) ΣΤΕΡΕΕΣ ΜΟΡΦΕΣ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ (1R,4R)-6'-ΦΘΟΡΟ-Ν,Ν-ΔΙΜΕΘΥΛ-4-ΦΑΙΝΥΛ-4',9'-ΔΙΥΔΡΟ-3´H-ΣΠΕΙΡΟ-[ΚΥΚΛΟΕΞΑΝΟ-1,1'-ΠΥΡΑΝΟ[3,4,b]ΙΝΔΟΛ]-4-ΑΜΙΝΗΣ
AR051043A1 (es) Forma cristalina de clorhidrato de (3-cian-1h-indol-7il)-[4-(4-fluorofenetil)-piperazin-1-il]-metanona
AR077692A1 (es) Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
ECSP11011053A (es) [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos
BRPI1010647A2 (pt) combinação de (a) um inibidor de fosfoinositídeo 3-quinase e (b) um composto antidiabético para uso no tratamento de doenças proliferativas
AR080203A1 (es) Formas solidas que comprenden una ciclopropilamida
MX2013007504A (es) Composiciones y metodos de uso de formas cristalinas de analogos de wortmanina.